Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin.

Autor: Vazirabad AF; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Noorolyai S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Baghbani E; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran., Mahboob S; Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Department of Food and Nutrition Security, Iran; Department of Biochemistry, Higher Education Institute of Rab-Rashid, Tabriz, Iran., Zargari F; Department of Medical Science, Marand Branch, Islamic Azad University, Marand, Iran., Rahmani S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Sorkhabi A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Montazami N; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Sameti P; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.
Jazyk: angličtina
Zdroj: Pathology, research and practice [Pathol Res Pract] 2022 Dec; Vol. 240, pp. 154194. Date of Electronic Publication: 2022 Nov 03.
DOI: 10.1016/j.prp.2022.154194
Abstrakt: Melanoma is the riskiest type of skin cancer. Its prevalence has been rapidly increased over the last three decades. SIX1, SIX2, SIX3, SIX4, SIX5, and SIX6 are members of the sine oculis homeobox (SIX) homolog family. It is imperative to identify new melanoma biomarkers to improve the predictive value for melanoma prognosis, which could enhance our understanding of carcinogenesis and tumor progression. In this study, we investigated whether silencing of SIX4 in a melanoma cell line (A375 cells) in combination with Cisplatin can affect the apoptosis and suppression of cell cycle progression, migration of the melanoma cells. MTT test and colony formation assay was applied to determine the IC50 of Cisplatin and the combined effect of SIX4 siRNA and Cisplatin on the viability and clonogenesis of the A-375 cells. qRT-PCR was performed to determine the c-myc, BCL-2, BAX, MMP-9, CXCR4, and Rock genes expression. Furthermore, flow cytometry was applied to evaluate apoptosis, autophagy, and the cell cycle status in different groups. Finally, wound healing assay was employed to evaluate the effect of this combination therapy on migratory capacity. SIX4 suppression increased the chemosensitivity of A-375 cells to Cisplatin and decreased its efficient dose. Furthermore, SIX4 suppression alongside Cisplatin reduced cell migration rate, arrested the cell cycle at the G1 phase, induced apoptosis by modulating the expression of apoptotic target genes, induced autophagy, and also significantly inhibits clonogenesis of A-375 cells. SIX4 plays a significant role in the chemosensitivity and pathogenesis of melanoma. Therefore, SIX4 suppression, in combination with Cisplatin, may be a promising therapeutic approach in treating melanoma.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier GmbH. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: